- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Xanax, Xanax XR, Niravam
Synonyms :
alprazolam
Class :
Antianxiety agents, Benzodiazepines, Antiemetics
Dosage forms & Strengths:
Tablet
0.25mg
0.5mg
1mg
2mg
Extended-release tablet
0.5mg
1mg
2mg
3mg
Orally disintegrating tablet
0.25mg
0.5mg
1mg
2mg
Oral solution
1mg/ml
Infusion solution
200mg/100 ml
200mg/20 ml
400mg/40 ml
400mg/200 ml
A dose of 0.25-0.5 mg orally every 6 to 8 hours is indicated for 3 to 4 days
Do not outreach the drug dose to more than 4 mg/day
An immediate-release tablet of 0.5 mg is recommended orally every 8 hours for 4 days
An extended-release tablet of 0.5-1 mg orally each day. May increase the dose by 1 mg/day every 3-4 days
Average dose is 3-6 mg orally each day
An immediate-release tablet of 0.5 mg is recommended orally every 8 hours for 4 days
An extended-release tablet of 0.5-1 mg orally each day. May increase the dose by 1 mg/day every 3-4 days
Average dose is 3-6 mg orally each day
1-4 mg of alprazolam orally every 8 hours a day
alprazolam is not recommended for children below 18 years
Refer to adult dosing for panic disorder and anxiety-related depression
Use a potent dose to prevent oversedation or ataxia
Older people sensitive to benzodiazepines should be given a reduced dose
may enhance the CNS depressant effect
may enhance the serum concentration
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may decrease the metabolism when combined
may enhance the serum concentration of CYP3A4 Inhibitors
may increase the risk of CNS depression when combined
They increase the concentration of alprazolam in serum
It increases the concentration of alprazolam in serum
it increases the concentration of CYP3A4 substrates in serum
CNS depressants increase the effect of flunarizine
it increases the CNS depressing effect of other CNS depressants
it increases the CNS depressing effect of other CNS depressants
it increases the CNS depressing effect of other CNS depressants
it increases the concentration of CYP3A4 in serum
CNS depressants increase the effect of thalidomide
when both drugs are combined, there may be a decreased effect of alprazolam by affecting hepatic or intestinal enzyme cyp3a4 metabolism
CYP3A strong enhancers of the small intestine may reduce the the bioavailability of alprazolam
it increases the effect of CNS depressants
CNS depressants increase the effect of orphenadrine
it increases the effect of CNS depressants
it increases the effect of CNS depressants
may have an increased effect of CNS depression when combined with Alprazolam
it increases the effect of CNS depressants
CNS depressants increase the effect of brexanolone
CYP3A4 inhibitors increase the concentration of carbamazepine in serum
it increases the effect of CNS depressants
it decreases the concentration of CYP3A4 substrates in serum
CYP3A4 inhibitors increase the concentration of flibanserin in serum
it increases the effect of CNS depressants
CYP3A4 inhibitors increase the concentration of midazolam in serum
CYP3A4 inhibitors increase the concentration of nimodipine in serum
it increases the effect of CNS depressants
CNS depressants increase the effect of rotigotine
CYP3A4 inhibitors increase the concentration of sirolimus in serum
CYP3A4 inhibitors increase the concentration of tacrolimus in serum alpra
it decreases the efficacy of antianxiety agents
CNS depressants may enhance the CNS depressant effect of cannabinoid-Containing products
CNS depressants may enhance the CNS depressant effect of cannabinoid-Containing products
CNS Depressants may enhance the CNS depressant effect of Opioid agonists
CNS Depressants may enhance the CNS depressant effect of Opioid agonists
CNS Depressants may enhance the CNS depressant effect of Opioid agonists
may enhance the serum concentration
may enhance the serum concentration
may enhance the serum concentration
may enhance the serum concentration
may enhance the serum concentration
It may enhance sedation when combined with tramadol
It may enhance sedation when combined with a shepherd's purse
Strong CYP3A4 inducers may lower the serum concentration of alprazolam
Strong CYP3A4 inducers may lower the serum concentration of alprazolam
Strong CYP3A4 inducers may lower the serum concentration of alprazolam
Strong CYP3A4 inducers may lower the serum concentration of alprazolam
Strong CYP3A4 inducers may lower the serum concentration of alprazolam
may enhance the concentration of serum when combined with alprazolam
may enhance the concentration of serum when combined with alprazolam
may enhance the concentration of serum when combined with alprazolam
may enhance the concentration of serum when combined with alprazolam
may enhance the concentration of serum when combined with alprazolam
alprazolam: they may diminish the serum concentration of CYP3A4 Inducers
alprazolam: they may diminish the serum concentration of CYP3A4 Inducers
It may enhance sedation when combined with codeine
It may diminish the effect when combined with griseofulvin by CYP3A4 metabolism
alprazolam: they may enhance the serum concentration of CYP3A4 Inhibitors
alprazolam: they may enhance the serum concentration of CYP3A4 Inhibitors
alprazolam: they may enhance the serum concentration of CYP3A4 Inhibitors
It may enhance sedation when combined with oxycodone
it may enhance the sedation when combined with lofexidine
The potential for increased CNS depression risk or seriousness occurs when alprazolam is used together with pinazepam
When captodiame is used together with alprazolam, There is a risk or seriousness of CNS depression is enhanced
It may diminish the metabolism when combined with nilvadipine
The potential for CNS depression may enhanced when alprazolam is used together with fencamfamin
Combining tegafur with alprazolam can reduce tegafur’s metabolism
When alprazolam is used together with medazepam, the risk or seriousness of CNS depression is enhanced
alprazolam may intensify paraldehyde's CNS depressant effects
When alprazolam is used together with levosulpiride, the risk or seriousness of CNS depression is enhanced
when alprazolam is used together with niaprazine, the risk or seriousness of CNS depression is enhanced
when both drugs are combined, there may be an increased effect of alprazolam by affecting hepatic or intestinal enzyme cyp3a4 metabolism
the effect of alprazolam is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
CYP3A4 inhibitors increase the concentration of alprazolam in serum
diphenoxylate, when used with alprazolam, increases sedation
nabilone and alprazolam, when used simultaneously, both increase the sedation
The interaction may enhance the drug serum levels of benzodiazepine agonist hypnotics
The interaction may enhance the drug serum levels of benzodiazepine agonist hypnotics
The interaction may enhance the drug serum levels of benzodiazepine agonist hypnotics
it increases the effect of CNS depressants
may increase the sedative effect
may enhance the serum concentration of CYP3A4 inhibitors
may have an increased adverse effect when combined with olanzapine.
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 Inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
it enhances the effect of alprazolam by diminishing the metabolism
it enhances the effect of alprazolam by diminishing the metabolism
it enhances the effect of alprazolam by diminishing the metabolism
it enhances the effect of alprazolam by diminishing the metabolism
alprazolam enhances the level of lithium by reducing renal clearance
